Miikka Vikkula/LinkedIn
Dec 25, 2025, 13:41
Miikka Vikkula on a Treatment Advance: How Sirolimus Dosing Can Be Adapted for Vascular Malformations
Miikka Vikkula, Vice President at International Society for the Study of Vascular Anomalies (ISSVA), shared a post on LinkedIn:
“Congratulations Emmanuel on this online publication showing how sirolimus treatment can be adapted to patients’ needs. Most patients with slow-flow vascular malformations benefit to some extent, and many experience significant symptom reduction even with intermittent dosing. This is a big step forward in the multimodal management of vascular malformations”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Apr 15, 2026, 15:33Peter Zdziarski: Will Glanzmann Thrombasthenia Patients Be Formally Recognized as Benefiting from SevenFACT?
-
Apr 15, 2026, 15:20Sonal Sonu: Blood Donation Myths in Rural Areas
-
Apr 15, 2026, 15:01Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 14:55Donald Correll: Key Risk Factors for Venous Thromboembolism
-
Apr 15, 2026, 14:48Fadwa Said Abdelazim: Is Vaping Really ‘Safer’ for the Blood Than Smoking?
-
Apr 15, 2026, 14:42Augustina Isioma Ikusemoro: An Underrecognized Cause of Severe Thrombocytopenia Following Transfusion
-
Apr 15, 2026, 14:42Caitlin Raymond: Augmented Intelligence Enhancing Human Capability Without Replacement
-
Apr 15, 2026, 14:39Pooja Choradia: Recognizing Pulmonary Embolism in Pregnancy Before It Is Too Late
-
Apr 15, 2026, 14:38Alessandra Bosch։ Understanding Haemostasis in Children and Its Challenges